Features | Partner Sites | Information | LinkXpress
Sign In
PZ HTL SA
GLOBETECH PUBLISHING LLC
GLOBETECH PUBLISHING LLC

Novel Method Enables Isolation of Nearly Pure Population of Mammary Gland Stem Cells

By BiotechDaily International staff writers
Posted on 25 Apr 2013
The surface protein marker CD1d is highly expressed on mammary gland stem cells (MaSCs), and the presence of this protein was used in a novel method to isolate a remarkably pure MaSC population.

CD1d is a member of the CD1 (cluster of differentiation 1) family of glycoproteins expressed on the surface of various human antigen-presenting cells. They are nonclassical major histocompatibility complex (MHC) proteins, related to the class I MHC proteins, and are involved in the presentation of lipid antigens to T-cells.

The partial purification of mouse MaSCs using a combination of cell surface markers has improved understanding of their role in normal development and breast tumorigenesis. However, despite the significant improvement in techniques for MaSC enrichment, there is presently no methodology that adequately isolates pure MaSCs.

To correct this lack, investigators at Cold Spring Harbor Laboratory (NY, USA) utilized the fact that MaSCs replicate very slowly to develop a method for their purification based on incorporation of a green fluorescent protein into the nuclei of various mammary cells including MaSCs. Since MaSCs replicate less often than other cell types, they retain more of the green fluorescent protein and can be isolated by cell sorting techniques that recognize CD1d.

The investigators reported in the April 11, 2013, online edition of the journal Proceedings of the National Academy of Sciences of the United States of America (PNAS) that working with a remarkably pure MaSC population, they were able to functionally characterize a set of MaSC-enriched genes and discovered factors controlling MaSC survival.

"With this advancement, we are now able to profile normal and cancer stem cells at a very high degree of purity, and perhaps point out which genes should be investigated as the next breast cancer drug targets," said senior author Dr. Gregory Hannon, professor of molecular biology at Cold Spring Harbor Laboratory.

Related Links:

Cold Spring Harbor Laboratory



comments powered by Disqus

Channels

Drug Discovery

view channel
Image: The nano-cocoon drug delivery system is biocompatible, specifically targets cancer cells, can carry a large drug load, and releases the drugs very quickly once inside the cancer cell. Ligands on the surface of the \"cocoon\" trick cancer cells into consuming it. Enzymes (the “worms\" in this image) inside the cocoon are unleashed once inside the cell, destroying the cocoon and releasing anticancer drugs into the cell (Photo courtesy of Dr. Zhen Gu, North Carolina State University).

Novel Anticancer Drug Delivery System Utilizes DNA-Based Nanocapsules

A novel DNA-based drug delivery system minimizes damage to normal tissues by utilizing the acidic microenvironment inside cancer cells to trigger the directed release of the anticancer drug doxorubicin (DOX).... Read more

Lab Technologies

view channel

Experimental Physicists Find Clues into How Radiotherapy Kills Cancer Cells

A new discovery in experimental physics has implications for a better determination of the process in which radiotherapy destroys cancer cells. Dr. Jason Greenwood from Queen’s University Belfast (Ireland) Center for Plasma Physics collaborated with scientists from Italy and Spain on the work on electrons, and published... Read more

Business

view channel

Interest in Commercial Applications for Proteomics Continues to Grow

Increasing interest in the field of proteomics has led to a series of agreements between private proteomic companies and academic institutions as well as deals between pharmaceutical companies and novel proteomics innovator biotech companies. Proteomics is the study of the structure and function of proteins.... Read more
 
Copyright © 2000-2014 Globetech Media. All rights reserved.